Skip to main content
$2.16 +0.00 (+0.00%) At close · Jul 24
Market Cap
$23.18M
Shares
10.73M

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$2.16 Open$2.16 Day$2.16–2.21 52W$1.65–3.07 Avg vol 30d23K Short int347K · 3.2% float · 15.8d Short vol13% Last earningsMay 13, 2026 DataJan 2020–Jul 2026 Filing10-Q · May 13

Up next

Next earnings call
Aug 12, 2026 Est · unconfirmed · in 2 wks
FQ1-27 quarter ends
~Sep 30, 2026 Est
filed May 13, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Neutral
      SellHoldBuy
      Technical Sell Momentum Very Weak Sentiment Bullish Fundamentals Excellent Quant / Vol High
      Market backdrop VIX 18.6 · elevated Equity put/call 0.79
      Technical
      price trend
      Sell
      50 / 200-day cross No cross
      Price vs 200-day avg −9%
      below
      Price vs 50-day avg −1%
      below
      RSI (14) 46
      neutral
      MACD trend Negative
      52-week position 36%
      mid-range
      Momentum
      relative strength
      Very Weak
      1-month return −1%
      trailing
      6-month return −16%
      trailing
      YTD return −17%
      this year
      Relative strength −23%
      vs S&P · 6-mo
      Sentiment
      smart money
      Bullish
      Trend (MA cross) No cross
      50d $2 › 200d $2 — 200d above 50d
      Institutional flow Accumulating
      5 of 37 funds reported for Jun 30 · net +23 sh shares · +1 new
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      3.23% of float · ▼ -0.4% MoM · 15.8 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      37 holders — mid 3-yr range
      Squeeze score 62
      elevated · 0–100
      Fundamentals
      Excellent
      Revenue growth +277%
      Y/Y
      Gross margin 166%
      contracting
      EPS growth +93%
      Y/Y
      Free cash flow $-2.2M
      Balance sheet $19.1M
      net cash
      Quant / Vol
      risk profile
      High
      Volatility 54%
      annualized · 1-yr
      Max drawdown −35%
      past year
      ATR 3.3%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Technicals

      trend & momentum for long-term holders Sell
      2 · 4 · 0
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      −9% Bearish
      Price vs 50-day avg
      −1% Neutral
      RSI (14)
      46 Neutral
      MACD trend
      Negative Bearish
      52-week position
      36% Neutral
      Market signals — smart money & positioning
      Bullish · 2 of 6
      Trend (MA cross) No cross
      50d $2 › 200d $2 — 200d above 50d
      Institutional flow Accumulating
      5 of 37 funds reported for Jun 30 · net +23 sh shares · +1 new
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      3.23% of float · ▼ -0.4% MoM · 15.8 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      37 holders — mid 3-yr range
      Price context
      position in its 52-week range
      52-wk low $2 Now $2 · 36% 52-wk high $3
      vs 200-day avg -9% vs 50-day avg -1%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from its earnings releases, calls, and filings
      Metric Latest Period YoY
      Adjusted EBITDA non-GAAP -$2.8M Q3 fiscal 2026
      Branded ADHD prescriptions dispensed through Aytu RxConnect 85% Q2 fiscal 2026
      Commercially insured MDD patients coverage 60% Q2 fiscal 2026

      Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

      Versus peers

      Drug Manufacturers - Specialty & Generic — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      AYTU
      Aytu Biopharma, Inc
      this stock
      $23.18M -16.9% +277.5% 3.2%
      TAK
      Takeda Pharmaceutical Co Ltd
      $55.06B +10.6% 0.1%
      GALDY
      Galderma Group AG/ADR
      $49.54B +2.5% 0.0%
      JHPCY
      Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
      $45.13B 0.0%
      HLN
      Haleon plc
      $43.07B -4.0% 0.3%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      38
      % held
      36.4%
      Reported
      5 of 37
      Top holder
      Nantahala Capital Managem…
      Held Float
      View
      Held by Funds
      Fund positions
      16
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      347.0K
      Days to cover
      15.8d
      Change
      -1.5K sh
      View
      Short Volume
      Short vol %
      13%
      As of
      Jul 24, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      693
      Value
      $1.6K
      As of
      Jun 24, 2026
      View
      Off-Exchange
      Off-exchange %
      56.7%
      Week of
      May 4, 2026
      Off-exch Lit
      View
      Financials
      Financials
      Revenue (FY)
      $66.4M
      Net income (FY)
      $-13.6M
      EPS diluted
      $-5.11
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Jun 25, 2026
      This year
      7
      View
      Earnings & Events
      Earnings Calls
      Last call
      May 13, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      AYTU +0.0% -1.4% -16.3% +0.5% -16.9%
      SPY -1.7% +0.7% +6.4% -1.2% +8.3%
      vs SPY +1.7% -2.0% -22.6% +1.6% -25.2%
      Key facts CIK 1385818 CUSIP 054754858 13F (30d) 5 filings 5 filers Visit website Investor relations